Headshot of Jing Wu

Jing Wu, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 37, Room 1142A
  • Bethesda, MD 20892
  • 240-760-6036
  • 301-480-5124
Neuro-Oncology Branch


Dr. Wu is a clinical neuro-oncologist who leads the Translational Research Program at the Neuro-Oncology Branch (NOB). Her clinical interests revolve around understanding challenges in neuro-oncology care, and developing laboratory and clinical research programs to understand glioma biology and investigate novel therapeutic approaches to improve patient clinical outcomes. Her goal is to observe phenotypes and gaps in knowledge through her clinical practice, in order to address these questions in the laboratory and subsequently develop hypothesis-based clinical trials. 

There are two facets to Dr. Wu’s research. First, she seeks to understand gliomas that exhibit an aggressive phenotype, in order to develop a diagnostic tool to monitor their transformation from low-grade to high-grade disease when they exhibit rapid growth. Her second goal is to test the efficacy of the multi-kinase inhibitor TG02 in clinical trials, in order to understand its effects on high-grade astrocytomas and IDH-mutant gliomas. 

Explore the NOB's Research Programs >

Areas of Expertise

Translational Research
Clinical Trial
IDH-Mutant Gliomas

Information for Patients

Learn about our multidisciplinary approach to patient care, our clinical trials and the highly specialized care teams who lead them.


Selected Key Publications

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.

Jing Wu J, Yuan Y, Priel DAL, Fink D, Peer CJ , Sissung TM, Su Y, Pang Y, Yu G, Butler MK, Mendoza TR, Vera E, Ahmad S, Bryla C, Lindsley M, Grajkowska E, Mentges K, Boris L, Antony R, Garren N, Siegel C, Lollo N, Cordova C, Aboud O, Theeler BJ, Burton EM, Penas-Prado M, Leeper H, Gonzales J, Armstrong TS, Calvo KR, Figg WD, Kuhns DB, Gallin JI, Gilbert MR.
Clinical Cancer Research. 27(12): 3298-3306, 2021. [ Journal Article ]

A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma.

Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu JM, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR.
Neuro-Oncology. 22: 1505–1515 , 2020. [ Journal Article ]

MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.

Su YT, Butler M, Zhang M, Zhang W, Song H, Hwang L, Tran A, Bash RE, Schorzman AN, Pang Y, Yu G, Zamboni WC, Wang X, Frye SV, Miller, Maric C, Terabe M, Gilbert MR, Earp III HS, Wu J.
Neuro-Oncology Advances. 2(1): 1–13, 2020. [ Journal Article ]

Novel Targeting of Transcription and Metabolism in Glioblastoma

Su YT, Chen R, Wang HR, Song H, Lappin H, Vasconcelos G, Lita A, Mric D, Celiku O, Li AG, Zhang W, Larion M, Abu-Asab M, Zhuang P,Yang CZ, Gilbert MR, Wu J
Clinical Cancer Research. 24: 1124-1137, 2018. [ Journal Article ]

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair

Lu YX, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su YT, Bautista W, Moon S, MacDonald J, Ewend ME, Gilbert MR, Yang CZ, Wu J
Cancer Research. 77: 1709-1718, 2017. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.


Postdoctoral Fellow (IRTA)
Olga Kim, M.D., Ph.D.
Postbaccalaureate Fellow (IRTA/CRTA)
Mythili Merchant
Research Fellow
Ying Pang, M.D., Ph.D.
Postbaccalaureate Fellow (IRTA/CRTA)
Alice Ranjan


Dr. Wu at a computer talking to Dr. Gilbert

Translational Research: Turning Patient Observations and Laboratory Findings into Clinical Trials

September 28, 2021

The Translational Research Program, led by Dr. Jing Wu, leverages laboratory research and patient observations to find new ways to treat brain and spine tumors, as well as improve patient outcomes. Read more >

Scientist in lab working at computer

Neuro-Oncology Branch 2020 Year in Review

January 22, 2021

Together, our clinical team, research laboratories, and staff have made meaningful advancements to improve outcomes for patients and their families impacted by brain and spine tumors. Read more >

Dr. Jing Wu and Madison Butler

Women Scientist Appreciation Month

March 1, 2020

In celebration of International Women and Girls in Science Day, we celebrated female scientists, physicians and mentors in the NOB that strive every day to make advances in ground-breaking research for brain and spine tumor patients. Read more >

Nanoparticles in the brain

FDA Grants Orphan Drug Designation to Zotiraciclib for the Treatment of Glioma

January 9, 2020

Dr. Jing Wu's investigational drug, zotiraciclib, received orphan drug approval by the FDA for the treatment of glioma, which comprises up to 30% of all brain and central nervous system tumors. Read more >

Patient-derived glioma stem cells treated with a PLK1 (serine/threonine-protein kinase) inhibitor and stained for nuclei (blue), alpha-tubulin (green), phospho-histone H3 (red).

New clinical trial will determine if gliomas respond to immunotherapy 

April 1, 2019

Dr. Jing Wu led a clinical trial to test the drug nivolumab in people with gliomas, in order to determine if patients whose tumors exhibit hypermutation features benefit the most from immune checkpoint inhibitors. Read more >